SCHEMBL16615524

SCHEMBL16615524

CCCN(CCC)S(=O)(=O)c1ccc(NC(=O)Cc2c(F)cccc2Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
KMT2A Q03164 3/20 0.59
ALDH1A1 P00352 3/20 0.59
MEN1 O00255 2/20 0.59
MAPT P10636 4/20 0.58
POLB P06746 3/20 0.58
CTDSP1 Q9GZU7 2/20 0.58
ESR1 P03372 1/20 0.58
LMNA P02545 3/20 0.56
CA12 O43570 4/20 0.54
CA9 Q16790 4/20 0.54
CA1 P00915 3/20 0.54
NPSR1 Q6W5P4 3/20 0.53
GAA P10253 2/20 0.53
HTT P42858 2/20 0.52
HPGD P15428 1/20 0.52
ESR2 Q92731 1/20 0.52
TSHR P16473 1/20 0.51
ABCC9 O60706 1/20 0.50
ABCC8 Q09428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615494 0.78 CA12 (0.70) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL16615487 0.77 MAPT (0.69) KMT2AALDH1A1MEN1MAPTPOLB
SCHEMBL17947769 0.73 POLB (1.00) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL24173209 0.73 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL4189849 0.72 CA9 (0.68) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL16615520 0.71 MAPT (0.66) KMT2AALDH1A1MEN1MAPTPOLB
SCHEMBL18301837 0.70 P2RX4 (0.69) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL17947763 0.69 CA9 (0.90) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL12851348 0.69 TP53 (0.67) SMN1; SMN2KMT2AALDH1A1MAPTPOLB
SCHEMBL2183796 0.68 SMN1; SMN2 (0.63) SMN1; SMN2KMT2APOLBLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
WO-2015042685-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF VALORISATION-RECHERCHE (CA) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF FBL, HNRNPA1, HNRNPUL1 SMN1; SMN2 81/4885KMT2A 1075/4885ALDH1A1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.